NCT00002218View on ClinicalTrials.gov

A Phase I Maximum Tolerated Dose Study of CI-1012 in Late-Stage HIV+ Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

CI-1012

Trial Locations (6)

20892

Natl Institutes of Health, Bethesda

32751

Central Florida Research Initiative, Maitland

48109

Univ of Michigan, Ann Arbor

84108

Univ of Utah Med School / Clinical Trials Ctr, Salt Lake City

92262

ViRx Inc, Palm Springs

94109

ViRx Inc, San Francisco

All Listed Sponsors
lead

Parke-Davis

INDUSTRY